Lowest Price Guaranteed From USD 4,499
Companies Covered
259
Pages
320
View Count
18574
The stem cell manufacturing market for CMO is estimated to be worth $293 million in 2019 and is expected to grow at CAGR of 18% during the forecast period. Advances in the fields of cell biology and regenerative medicine have led to the development of a variety of stem cell-based therapies for many cardiovascular, oncological, metabolic and musculoskeletal disorders. Driven by the revenues generated from stem cell therapies, the regenerative medicine market is anticipated to generate revenues worth USD 100 billion by 2030. With a promising pipeline of over 200 stem cell therapy candidates, it has become essential for developers to scale up the production of stem cells therapeutic interventions. Given that stem cell therapy manufacturing requires highly regulated, state-of-the-art technologies, it is difficult for stakeholders to establish in-house expertise for large-scale manufacturing of stem cell therapies. As a result, stem cell therapy developers have begun outsourcing their manufacturing operations to contract manufacturing organizations (CMOs). Specifically, small and mid-sized players in this sector tend to outsource a substantial proportion of clinical and commercial-scale manufacturing processes to contract service providers. In addition, even big pharma players, with established in-house capabilities, are gradually entering into long-term business relationships with CMOs in order to optimize resource utilization and manage costs.
![]() |
![]() |
![]() |
According to a recent Nice Insight CDMO survey, about 55% of 700 respondents claimed to have collaborated with a contract service provider for clinical and commercial-scale product development requirements. Considering the prevalent trends, we believe that the stem cell therapy manufacturing market is poised to grow at a steady pace, driven by a robust pipeline of therapy candidates and technological advances aimed at mitigating challenges posed by conventional methods of production of stem cells. Amidst tough competition, the availability of cutting-edge tools and technologies has emerged as a differentiating factor and is likely to grant a competitive advantage to certain CMOs over other players in the industry. Infact, the demand for these contract manufacturing services is likely to be fueled by the increase in number of stem cell therapies being developed for treatment of COVID-19. For instance, stem cell therapy developers such as Athersys and Lattice Biologics have already taken initiatives to find solutions to the fight the novel Coronavirus outbreak.
Examples of key stem cell manufacturers engaged in stem cell manufacturing market (which have also been profiled in this market report; the complete list of stem cell companies is available in the full report) include FUJIFILM Cellular Dynamics, GenCure, Progenitor Cell Therapy (PCT), Waisman Biomanufacturing, WuXi Advanced Therapies, BioNTech Innovative Manufacturing Services, Cell and Gene Therapy Catapult, Lonza, Roslin Cells, MEDINET and Nikon CeLL innovation. This market report includes an easily searchable excel database of all the stem cell companies, worldwide.
Several recent developments have taken place in the field of stem cell manufacturing market. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.
The “Stem Cell Manufacturing Market, 2019 – 2030” market report features an extensive study on current market landscape, market size, market share, market growth, market trends, market value, market forecast, market outlook, statistics and future opportunities of the stem cell manufacturing market. The market research report features in-depth analyses, highlighting the capabilities of various stem cell therapy CMOs.
![]() |
![]() |
![]() |
Amongst other elements, the market research report includes:
The key objective of stem cell manufacturing market report is to provide a detailed market analysis in order to estimate the existing market size, market share, market growth, market trends, market value, market forecast, market outlook, statistics and future opportunity for stem cell manufacturing market during the forecast period. Based on parameters, such as increase in number of clinical studies, target patient population, anticipated adoption of stem cell therapies and expected variation in manufacturing costs, we have provided an informed estimate of the likely evolution of the market in the mid to long term, for the forecast period 2019-2030. In order to provide a detailed future outlook, our projections have been segmented on the basis of [A] source of stem cells (autologous and allogenic), [B] types of stem cells (adult, embryonic and induced pluripotent), [C] size of contract service provider company (small-sized, mid-sized and large), [D] scale of operation (preclinical, clinical and commercial) and [E] key geographical regions (North America, Europe and Asia and rest of the world). To account for the uncertainties associated with the manufacturing of stem cell therapies and to add robustness to our model, we have provided three market forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.
The opinions and insights presented in the market report were influenced by discussions held with senior stakeholders in the industry. The market research report features detailed transcripts of interviews held with the following industry stakeholders:
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this market report are in USD, unless otherwise specified.